<DOC>
	<DOCNO>NCT00314509</DOCNO>
	<brief_summary>The aim study compare efficacy two dos fix combination ciclesonide/formoterol fumarate versus ciclesonide alone versus formoterol fumarate alone patient asthma . The study duration consist baseline period ( 2 3 week ) treatment period ( 8 week ) . The study provide data safety tolerability ciclesonide/formoterol fumarate .</brief_summary>
	<brief_title>Safety Tolerability Ciclesonide Formoterol Fumarate Inhaled Once Daily Patients With Asthma ( 18 75 ) ( BY9010/M1-506 )</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Ciclesonide</mesh_term>
	<criteria>Main Written inform consent Good health exception bronchial asthma ( least 6 month ) FEV1 &gt; 60 % &lt; 80 % predict ( pretreated inhale steroid ) FEV1 &gt; 60 % ≤ 85 % predict ( pretreated inhale steroid combination asthma controller ) Main Concomitant severe disease disease contraindication use inhaled steroid longacting beta2agonists Chronic obstructive pulmonary disease ( COPD ) , i.e . chronic bronchitis emphysema , and/or relevant lung disease cause alternate impairment pulmonary function Current smoking cessation smoking within last 6 month previous smoke smoke history ≥ 10 cigarette packyears Use drug allow Pregnancy intention become pregnant course study , breast feeding , lack safe contraception woman childbearing potential</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Ciclesonide</keyword>
	<keyword>Formoterol Fumarate</keyword>
	<keyword>Long-acting beta2-agonists</keyword>
	<keyword>LABA</keyword>
	<keyword>Steroids</keyword>
</DOC>